Examples of 'pembrolizumab' in a sentence
Meaning of "pembrolizumab"
pembrolizumab (noun) - a drug used in cancer treatment, especially for melanoma and lung cancer. It is a type of immunotherapy that works by helping the immune system fight cancer cells. For example, 'The patient's oncologist recommended pembrolizumab as part of their treatment plan.'
Show more definitions
- A drug that targets the programmed cell death 1 (PD-1) receptor, intended for use in treating metastatic melanoma.
How to use "pembrolizumab" in a sentence
Basic
Advanced
pembrolizumab
It is unknown whether pembrolizumab is secreted in human milk.
Pembrolizumab is a type of immunotherapy called a checkpoint inhibitor.
Keytruda contains the active substance pembrolizumab.
Crossover to pembrolizumab was permitted following progressive disease.
Approved drugs include nivolumab and pembrolizumab.
The safety profile with pembrolizumab continued to be favorable.
Pembrolizumab and chemotherapy in combination seen as highly effective.
The medicine contains the active substance pembrolizumab.
He went on pembrolizumab and had a complete response.
There is no information on overdose with pembrolizumab.
Treatment with pembrolizumab has been mostly studied in adults.
It contains the active substance pembrolizumab.
Pembrolizumab was very well tolerated.
There are no data on the use of pembrolizumab in pregnant women.
Hypophysitis has also been reported in patients receiving pembrolizumab.
See also
Pembrolizumab was also well tolerated.
Animal reproduction studies have not been conducted with pembrolizumab.
Pembrolizumab works by helping the immune system to fight cancer.
No clinical data are available on the possible effects of pembrolizumab on fertility.
Pembrolizumab has not been studied in patients with severe renal impairment.
The active substance is pembrolizumab.
Patients were treated with pembrolizumab until disease progression or unacceptable toxicity.
Animal fertility studies have not been conducted with pembrolizumab.
Four patients in the pembrolizumab group died of causes related to treatment.
No formal pharmacokinetic drug interaction studies have been conducted with pembrolizumab.
Pembrolizumab can make some glands that make hormones inflamed.
Tumor mutational burden not significantly associated with efficacy of pembrolizumab.
Pembrolizumab may increase your risk for possible organ transplant rejection.
Warning comes two months after pembrolizumab trials halted due to deaths.
Pembrolizumab may have a minor influence on the ability to drive and use machines.
We aimed to assess the efficacy and safety of pembrolizumab in this patient population.
Pembrolizumab is dosed via the intravenous route and therefore is immediately and completely bioavailable.
Immune checkpoint inhibitors such as pembrolizumab or nivolumab are another option for these people.
Pembrolizumab is administered via the intravenous route and therefore is immediately and completely bioavailable.
Your doctor may stop giving you pembrolizumab until the rash improves.
Pembrolizumab is an effective option for some people with advanced stomach and gastroesophageal junction cancers.
He stepped down from his role to lead clinical development of pembrolizumab for lung cancer.
The safety profile of Pembrolizumab was consistent with that observed in previously reported studies.
Patients with active infections occurring during treatment with pembrolizumab were managed with appropriate medical therapy.
Endpoint Pembrolizumab combination therapy.
There was no statistically significant difference between pembrolizumab and chemotherapy with respect to PFS.
Pembrolizumab may cause these side effects,.
What KEYTRUDA contains The active substance is pembrolizumab.
Chemotherapy Pembrolizumab combination therapy.
In a specific embodiment, the inhibitor is pembrolizumab.
Pembrolizumab showed a manageable safety profile ".
This trial shows that pembrolizumab was non-inferior to chemo.
Pembrolizumab is most commonly associated with immune-related adverse reactions.
The recommended dose is 2 mg of pembrolizumab per kilogram of your body weight.
Use of pembrolizumab combined with chemotherapy improved survival to an average of 13 months.
